NCT00703547 - A First Time in Human Study of GSK586529 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 28, 2008

Primary Completion Date

April 11, 2008

Study Completion Date

April 11, 2008

Conditions

Depressive Disorder and Anxiety Disorders

Interventions

DRUG

GSK586529 capsules

GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.

DRUG

GSK586529 tablets

GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.

DRUG

Placebo

Placebo tablets and capsules will be provided to subjects.

Trial Locations (1)

NW10 7NS

GSK Investigational Site, London